# Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

> **NCT07470489** · PHASE2 · NOT_YET_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (estimated)

## Conditions studied

- Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** Cemiplimab
- **DRUG:** Zanzalintinib

## Key facts

- **NCT ID:** NCT07470489
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2030-09-01
- **Final completion:** 2032-09-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07470489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07470489, "Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07470489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*